CoChat
Sign Up
Cited by 408

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

The APOBEC Protein Family: United by Structure, Divergent in Function

Salter, Jason D., Bennett, Ryan P., Smith, Harold C.·2016·Trends in Biochemical Sciences
DOI 10.1016/j.tibs.2016.05.001PMC PMC4930407
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.tibs.2016.05.001

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • APOBEC proteins play an important role in immune responses against DNA and RNA viral pathogens.

    “Since APOBEC proteins play an important role in immune responses against DNA and RNA viral pathogens (Refs.19–22 and references therein), we also investigated the possible effects of the three APOBECs on SARS-CoV-2 replication and progeny production in our experimental system (Fig. 5A).”

    From The roles of APOBEC-mediated RNA editing in SARS-CoV-2 mutations, replication and fitness (2022) · cites this paper as [20]

  • The APOBEC proteins are a family of cytosine deaminases that can deaminate cytosine to uracil (C-to-U) in single-stranded nucleic acids and function in innate and adaptive immune responses to viral pathogens.

    “The APOBEC proteins are a family of cytosine deaminases that can deaminate cytosine to uracil (C-to-U) in single-stranded nucleic acids and function in a variety of biological processes, including innate and adaptive immune responses to viral pathogens (Refs.19–22 and references therein).”

    From The roles of APOBEC-mediated RNA editing in SARS-CoV-2 mutations, replication and fitness (2022) · cites this paper as [20]

  • The pro-viral effect of A3A contrasts with the known anti-viral effect of APOBECs.

    “These pro-viral effect of A3A contrast to the known anti-viral effect of APOBECs19–22.”

    From The roles of APOBEC-mediated RNA editing in SARS-CoV-2 mutations, replication and fitness (2022) · cites this paper as [20]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 142

  1. Chen, 1987, Apolipoprotein B-48 is the product of a messenger RNA with an organ- specific in-frame stop codon, Science, 238, 363, 10.1126/science.3659919 · DOI
  2. Powell, 1987, A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine, Cell, 50, 831, 10.1016/0092-8674(87)90510-1 · DOI
  3. Rogozin, 2007, Evolution and diversification of lamprey antigen receptors: evidence for involvement of an AID–APOBEC family cytosine deaminase, Nat. Immunol., 8, 647, 10.1038/ni1463 · DOI
  4. Conticello, 2008, The AID/APOBEC family of nucleic acid mutators, Genome Biol., 9, 229, 10.1186/gb-2008-9-6-229 · DOI
  5. LaRue, 2009, Guidelines for naming nonprimate APOBEC3 genes and proteins, J. Virol., 83, 494, 10.1128/JVI.01976-08 · DOI
  6. Teng, 1993, Molecular cloning of an apolipoprotein B messenger RNA editing protein, Science, 260, 1816, 10.1126/science.8511591 · DOI · Paper page
  7. Jarmuz, 2002, An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22, Genomics, 79, 285, 10.1006/geno.2002.6718 · DOI
  8. Muramatsu, 1999, Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells, J. Biol. Chem. 1999., 274, 18470
  9. Li, 2004, The generation of antibody diversity through somatic hypermutation and class switch recombination, Genes Dev., 18, 1, 10.1101/gad.1161904 · DOI
  10. Dickerson, 2003, AID mediates hypermutation by deaminating single stranded DNA, J. Exp. Med., 197, 1291, 10.1084/jem.20030481 · DOI
  11. Honjo, 2004, AID: how does it aid antibody diversity?, Immunity, 20, 659, 10.1016/j.immuni.2004.05.011 · DOI
  12. Papavasiliou, 2002, Somatic hypermutation of immunoglobulin genes: merging mechanisms for genetic diversity, Cell, 109, S35, 10.1016/S0092-8674(02)00706-7 · DOI
  13. Sheehy, 2002, Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein, Nature, 418, 646, 10.1038/nature00939 · DOI
  14. Smith, 2011, APOBEC3G: a double agent in defense, Trends Biochem. Sci., 36, 239, 10.1016/j.tibs.2010.12.003 · DOI
  15. Refsland, 2010, Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction, Nuc. Acids Res., 38, 4274, 10.1093/nar/gkq174 · DOI
  16. Harris, 2003, DNA deamination mediates innate immunity to retroviral infection, Cell, 113, 803, 10.1016/S0092-8674(03)00423-9 · DOI
  17. Revy, 2000, Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the hyper-IgM syndrome (HIGM2), Cell, 102, 565, 10.1016/S0092-8674(00)00079-9 · DOI
  18. Aydin, 2014, Structure-guided analysis of the human APOBEC3–HIV restrictome, Structure, 22, 668, 10.1016/j.str.2014.02.011 · DOI
  19. Hultquist, 2011, Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1, J. Virol., 85, 11220, 10.1128/JVI.05238-11 · DOI
  20. Rogozin, 2005, APOBEC4, a new member of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases predicted by computational analysis, Cell Cycle, 4, 1281, 10.4161/cc.4.9.1994 · DOI
  21. Conticello, 2005, Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases, Mol. Biol. Evol., 22, 367, 10.1093/molbev/msi026 · DOI
  22. Okuyama, 2012, Excessive activity of apolipoprotein B mRNA editing enzyme catalytic polypeptide 2 (APOBEC2) contributes to liver and lung tumorigenesis, Int. J. Cancer, 130, 1294, 10.1002/ijc.26114 · DOI
  23. Sato, 2010, Deficiency in APOBEC2 leads to a shift in muscle fiber type, diminished body mass, and myopathy, J. Biol. Chem., 285, 7111, 10.1074/jbc.M109.052977 · DOI
  24. Ortiz, M. et al. Patterns of evolution of host proteins involved in retroviral pathogenesis. Retrovirology 3, 11 · DOI
  25. Munk, 2012, An ancient history of gene duplications, fusions and losses in the evolution of APOBEC3 mutators in mammals, BMC Evol. Biol., 12, 71, 10.1186/1471-2148-12-71 · DOI
  26. Etienne, 2015, The role of the antiviral APOBEC3 gene family in protecting chimpanzees against lentiviruses from monkeys, PLoS Pathog., 11, e1005149, 10.1371/journal.ppat.1005149 · DOI
  27. Schumann, 2007, APOBEC3 proteins: major players in intracellular defence against LINE-1-mediated retrotransposition, Biochem. Soc. Trans., 35, 637, 10.1042/BST0350637 · DOI
  28. Koning, 2009, Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets, J. Virol., 83, 9474, 10.1128/JVI.01089-09 · DOI
  29. Peng, 2007, Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression, Blood, 110, 393, 10.1182/blood-2006-10-051763 · DOI
  30. Stopak, 2007, Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells, J. Biol. Chem., 282, 3539, 10.1074/jbc.M610138200 · DOI
  31. Rose, 2004, Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus, J. Biol. Chem., 279, 41744, 10.1074/jbc.M406760200 · DOI
  32. Sarkis, 2006, STAT1-independent cell type-specific regulation of antiviral APOBEC3G by IFN-alpha, J. Immunol., 177, 4530, 10.4049/jimmunol.177.7.4530 · DOI
  33. Anderson, 2015, Transcriptional regulation of APOBEC3 antiviral immunity through the CBF-beta/RUNX axis, Sci. Adv., 1, e1500296, 10.1126/sciadv.1500296 · DOI
  34. Desimmie, 2014, Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all, J. Mol. Biol., 426, 1220, 10.1016/j.jmb.2013.10.033 · DOI
  35. Chaipan, 2013, APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages, J. Virol., 87, 444, 10.1128/JVI.00676-12 · DOI
  36. Sakurai, 2015, APOBEC3H polymorphisms associated with the susceptibility to HIV-1 infection and AIDS progression in Japanese, Immunogenetics, 67, 253, 10.1007/s00251-015-0829-2 · DOI
  37. Refsland, 2014, Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity, PLoS Genet., 10, e1004761, 10.1371/journal.pgen.1004761 · DOI
  38. Naruse, 2015, APOBEC3H polymorphisms and susceptibility to HIV-1 infection in an Indian population, J. Hum. Genet., 61, 263, 10.1038/jhg.2015.136 · DOI
  39. OhAinle, 2008, Antiretroelement activity of APOBEC3H was lost twice in recent human evolution, Cell Host Microbe, 4, 249, 10.1016/j.chom.2008.07.005 · DOI
  40. Yu, 2004, APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication, J. Biol. Chem., 279, 53379, 10.1074/jbc.M408802200 · DOI
  41. Wang, 2008, Distinct viral determinants for the packaging of human cytidine deaminases APOBEC3G and APOBEC3C, Virology, 377, 71, 10.1016/j.virol.2008.04.012 · DOI
  42. Bonvin, 2006, Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication, Hepatology, 43, 1364, 10.1002/hep.21187 · DOI
  43. Bulliard, 2011, Structure-function analyses point to a polynucleotide-accommodating groove essential for APOBEC3A restriction activities, J. Virol., 85, 1765, 10.1128/JVI.01651-10 · DOI
  44. Thielen, 2010, Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms, J. Biol. Chem., 285, 27753, 10.1074/jbc.M110.102822 · DOI
  45. Sharma, 2015, APOBEC3A cytidine deaminase induces RNA editing in monocytes and macrophages, Nat. Commun., 6, 6881, 10.1038/ncomms7881 · DOI · Paper page
  46. Bransteitter, 2003, Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase, Proc. Natl. Acad. Sci. U.S.A., 100, 4102, 10.1073/pnas.0730835100 · DOI
  47. Nonaka, 2009, Carboxy-terminal domain of AID required for its mRNA complex formation in vivo, Proc. Natl. Acad. Sci. U.S.A., 106, 2747, 10.1073/pnas.0812957106 · DOI
  48. Smith, 2012, Functions and regulation of the APOBEC family of proteins, Semin. Cell Dev. Biol., 23, 258, 10.1016/j.semcdb.2011.10.004 · DOI
  49. Yang, 1997, Multiple protein domains determine the cell type-specific nuclear distribution of the catalytic subunit required for apolipoprotein B mRNA editing, Proc. Natl. Acad. Sci. U.S.A., 94, 13075, 10.1073/pnas.94.24.13075 · DOI
  50. Ito, 2004, Activation-induced cytidine deaminase shuttles between nucleus and cytoplasm like apolipoprotein B mRNA editing catalytic polypeptide 1, Proc. Natl. Acad. Sci. U.S.A., 101, 1975, 10.1073/pnas.0307335101 · DOI
  51. Sowden, 2002, The editosome for cytidine to uridine mRNA editing has a native complexity of 27S: identification of intracellular domains containing active and inactive editing factors, J. Cell Sci., 115, 1027, 10.1242/jcs.115.5.1027 · DOI
  52. Methot, 2015, Consecutive interactions with HSP90 and eEF1A underlie a functional maturation and storage pathway of AID in the cytoplasm, J. Exp. Med., 212, 581, 10.1084/jem.20141157 · DOI
  53. Bennett, 2008, Nuclear exclusion of the HIV-1 host defense factor APOBEC3G requires a novel cytoplasmic retention signal and is not dependent on RNA binding, J. Biol. Chem., 283, 7320, 10.1074/jbc.M708567200 · DOI
  54. Zhen, 2012, Reduced APOBEC3H variant anti-viral activities are associated with altered RNA binding activities, PLoS ONE, 7, e38771, 10.1371/journal.pone.0038771 · DOI
  55. Gallois-Montbrun, 2007, Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules, J. Virol., 81, 2165, 10.1128/JVI.02287-06 · DOI
  56. Wichroski, 2006, Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies, PLoS Pathog., 2, e41, 10.1371/journal.ppat.0020041 · DOI
  57. McDougall, 2011, Direct evidence that RNA inhibits APOBEC3G ssDNA cytidine deaminase activity, Biochem. Biophys. Res. Commun., 412, 612, 10.1016/j.bbrc.2011.08.009 · DOI
  58. Wu, 2008, Alternative splicing regulates activation-induced cytidine deaminase (AID): implications for suppression of AID mutagenic activity in normal and malignant B cells, Blood, 112, 4675, 10.1182/blood-2008-03-145995 · DOI
  59. Dorsett, 2008, MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc–Igh translocation, Immunity, 28, 630, 10.1016/j.immuni.2008.04.002 · DOI
  60. Takizawa, 2008, AID expression levels determine the extent of cMyc oncogenic translocations and the incidence of B cell tumor development, J. Exp. Med., 205, 1949, 10.1084/jem.20081007 · DOI
  61. Hersberger, 2003, Regulatable liver expression of the rabbit apolipoprotein B mRNA-editing enzyme catalytic polypeptide 1 (APOBEC-1) in mice lacking endogenous APOBEC-1 leads to aberrant hyperediting, Biochem. J., 369, 255, 10.1042/bj20020694 · DOI
  62. Yamanaka, 1997, A novel translational repressor mRNA is edited extensively in livers containing tumors caused by the transgene expression of the apoB mRNA-editing enzyme, Genes Dev., 11, 321, 10.1101/gad.11.3.321 · DOI
  63. Saraconi, 2014, The RNA editing enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is present in esophageal adenocarcinomas, Genome Biol., 15, 417, 10.1186/s13059-014-0417-z · DOI
  64. Lackey, 2012, APOBEC3B and AID have similar nuclear import mechanisms, J. Mol. Biol., 419, 301, 10.1016/j.jmb.2012.03.011 · DOI
  65. Burns, 2013, APOBEC3B is an enzymatic source of mutation in breast cancer, Nature, 494, 366, 10.1038/nature11881 · DOI
  66. Henderson, 2015, APOBEC3 genes: retroviral restriction factors to cancer drivers, Trends Mol. Med., 21, 274, 10.1016/j.molmed.2015.02.007 · DOI
  67. Vieira, 2014, Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B, MBio, 5
  68. Land, 2013, Endogenous APOBEC3A DNA cytosine deaminase is cytoplasmic and nongenotoxic, J. Biol. Chem., 288, 17253, 10.1074/jbc.M113.458661 · DOI
  69. Caval, 2014, A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3′UTR enhances chromosomal DNA damage, Nat. Commun., 5, 5129, 10.1038/ncomms6129 · DOI
  70. Chan, 2015, An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers, Nat. Genet., 47, 1067, 10.1038/ng.3378 · DOI · Paper page
  71. Prochnow, 2007, The APOBEC-2 crystal structure and functional implications for the deaminase AID, Nature, 445, 447, 10.1038/nature05492 · DOI
  72. Krzysiak, 2012, APOBEC2 is a monomer in solution: implications for APOBEC3G models, Biochemistry, 51, 2008, 10.1021/bi300021s · DOI
  73. Chen, 2008, Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G, Nature, 452, 116, 10.1038/nature06638 · DOI
  74. Furukawa, 2009, Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G, EMBO J., 28, 440, 10.1038/emboj.2008.290 · DOI
  75. Harjes, 2009, An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model, J. Mol. Biol., 389, 819, 10.1016/j.jmb.2009.04.031 · DOI
  76. Byeon, 2013, NMR structure of human restriction factor APOBEC3A reveals substrate binding and enzyme specificity, Nat. Commun., 4, 1890, 10.1038/ncomms2883 · DOI
  77. Kouno, 2015, Structure of the Vif-binding domain of the antiviral enzyme APOBEC3G, Nat. Struct. Mol. Biol., 22, 485, 10.1038/nsmb.3033 · DOI
  78. Kitamura, 2012, The APOBEC3C crystal structure and the interface for HIV-1 Vif binding, Nat. Struct. Mol. Biol., 19, 1005, 10.1038/nsmb.2378 · DOI
  79. Holden, 2008, Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications, Nature, 456, 121, 10.1038/nature07357 · DOI
  80. Shandilya, 2010, Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces, Structure, 18, 28, 10.1016/j.str.2009.10.016 · DOI
  81. Lu, 2015, Crystal Structure of DNA cytidine deaminase ABOBEC3G catalytic deamination domain suggests a binding mode of full-length enzyme to single-stranded DNA, J. Biol. Chem., 290, 4010, 10.1074/jbc.M114.624262 · DOI
  82. Shi, 2015, Crystal structure of the DNA deaminase APOBEC3B catalytic domain, J. Biol. Chem., 290, 28120, 10.1074/jbc.M115.679951 · DOI
  83. Bohn, 2013, Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain, Structure, 21, 1042, 10.1016/j.str.2013.04.010 · DOI
  84. Siu, 2013, Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F, Nat. Commun., 4, 2593, 10.1038/ncomms3593 · DOI
  85. Nakashima, 2015, Structural Insights into HIV-1 Vif–APOBEC3F Interaction, J. Virol., 90, 1034, 10.1128/JVI.02369-15 · DOI
  86. Wedekind, 2006, Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular mass ribonucleoprotein particles from dimeric subunits, J. Biol. Chem., 281, 38122, 10.1074/jbc.C600253200 · DOI
  87. Betts, 1994, Cytidine deaminase. The 2.3 A crystal structure of an enzyme: transition-state analog complex, J. Mol. Biol., 235, 635, 10.1006/jmbi.1994.1018 · DOI
  88. Polevoda, 2015, RNA binding to APOBEC3G induces the disassembly of functional deaminase complexes by displacing single-stranded DNA substrates, Nuc. Acids Res., 43, 9434, 10.1093/nar/gkv970 · DOI
  89. Rathore, 2013, The local dinucleotide preference of APOBEC3G can be altered from 5′-CC to 5′-TC by a single amino acid substitution, J. Mol. Biol., 425, 4442, 10.1016/j.jmb.2013.07.040 · DOI
  90. Marx, 2015, Zinc enhancement of cytidine deaminase activity highlights a potential allosteric role of loop-3 in regulating APOBEC3 enzymes, Sci. Rep., 5, 18191, 10.1038/srep18191 · DOI
  91. Bohn, 2015, The ssDNA mutator APOBEC3A is regulated by cooperative dimerization, Structure, 23, 903, 10.1016/j.str.2015.03.016 · DOI
  92. Logue, 2014, A DNA sequence recognition loop on APOBEC3A controls substrate specificity, PLoS ONE, 9, e97062, 10.1371/journal.pone.0097062 · DOI
  93. Navarro, 2005, Complementary function of the two catalytic domains of APOBEC3G, Virology, 333, 374, 10.1016/j.virol.2005.01.011 · DOI
  94. Iwatani, 2006, Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect, J. Virol., 80, 5992, 10.1128/JVI.02680-05 · DOI
  95. Shlyakhtenko, 2015, APOBEC3G interacts with ssDNA by two modes: AFM studies, Sci. Rep., 5, 15648, 10.1038/srep15648 · DOI
  96. Salter, 2009, A hydrodynamic analysis of APOBEC3G reveals a monomer–dimer–tetramer self-association that has implications for anti-HIV function, Biochemistry, 48, 10685, 10.1021/bi901642c · DOI
  97. McDougall, 2011, Deaminase activity on single-stranded DNA (ssDNA) occurs in vitro when APOBEC3G cytidine deaminase forms homotetramers and higher-order complexes, J. Biol. Chem., 286, 30655, 10.1074/jbc.M111.269506 · DOI
  98. Shlyakhtenko, 2011, Atomic force microscopy studies provide direct evidence for dimerization of the HIV restriction factor APOBEC3G, J. Biol. Chem., 286, 3387, 10.1074/jbc.M110.195685 · DOI
  99. Anant, 1995, Apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, is a novel RNA-binding protein, J. Biol. Chem., 270, 14762, 10.1074/jbc.270.24.14762 · DOI
  100. Prohaska, 2014, The multifaceted roles of RNA binding in APOBEC cytidine deaminase functions, Wiley Interdiscip. Rev. RNA, 5, 493, 10.1002/wrna.1226 · DOI
  101. Friew, 2009, Intracellular interactions between APOBEC3G, RNA, and HIV-1 Gag: APOBEC3G multimerization is dependent on its association with RNA, Retrovirology, 6, 56, 10.1186/1742-4690-6-56 · DOI
  102. Huthoff, 2007, Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and virion encapsidation, J. Virol., 81, 3807, 10.1128/JVI.02795-06 · DOI
  103. Navaratnam, 1998, Escherichia coli cytidine deaminase provides a molecular model for ApoB RNA editing and a mechanism for RNA substrate recognition, J. Mol. Biol., 275, 695, 10.1006/jmbi.1997.1506 · DOI
  104. Galloway, 2010, APOBEC-1 complementation factor (ACF) forms RNA-dependent multimers, Biochem. Biophys. Res. Commun., 398, 38, 10.1016/j.bbrc.2010.06.021 · DOI
  105. Maris, 2005, NMR structure of the apoB mRNA stem-loop and its interaction with the C to U editing APOBEC1 complementary factor, RNA, 11, 173, 10.1261/rna.7190705 · DOI · Paper page
  106. Oka, 1997, Tissue-specific inhibition of apolipoprotein B mRNA editing in the liver by adenovirus-mediated transfer of a dominant negative mutant APOBEC-1 leads to increased low density lipoprotein in mice, J. Biol. Chem., 272, 1456, 10.1074/jbc.272.3.1456 · DOI
  107. Lau, 1997, Cloning of an Apobec-1-binding protein that also interacts with apolipoprotein B mRNA and evidence for its involvement in RNA editing, J. Biol. Chem., 272, 1452, 10.1074/jbc.272.3.1452 · DOI
  108. Lau, 1994, Dimeric structure of a human apolipoprotein B mRNA editing protein and cloning and chromosomal localization of its gene, Proc. Natl. Acad. Sci. U.S.A., 91, 8522, 10.1073/pnas.91.18.8522 · DOI
  109. Bhagwat, 2008, Is AID a monomer in solution?, DNA Repair (Amst), 7, 349, 10.1016/j.dnarep.2007.10.009 · DOI
  110. Brar, 2008, Activation-induced deaminase, AID, is catalytically active as a monomer on single-stranded DNA, DNA Repair (Amst), 7, 77, 10.1016/j.dnarep.2007.08.002 · DOI
  111. Li, 2014, APOBEC3 multimerization correlates with HIV-1 packaging and restriction activity in living cells, J. Mol. Biol., 426, 1296, 10.1016/j.jmb.2013.12.014 · DOI
  112. Chaudhuri, 2004, Replication protein A interacts with AID to promote deamination of somatic hypermutation targets, Nature, 430, 992, 10.1038/nature02821 · DOI
  113. Svarovskaia, 2004, Human APOBEC3G is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs, J. Biol. Chem., 279, 35822, 10.1074/jbc.M405761200 · DOI
  114. Wang, 2008, Interaction with 7SL RNA but not with HIV-1 genomic RNA or P bodies is required for APOBEC3F virion packaging, J. Mol. Biol., 375, 1098, 10.1016/j.jmb.2007.11.017 · DOI
  115. Huthoff, 2009, RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1, PLoS Pathog., 5, e1000330, 10.1371/journal.ppat.1000330 · DOI
  116. Chelico, 2010, A structural model for deoxycytidine deamination mechanisms of the HIV-1 inactivation enzyme APOBEC3G, J. Biol. Chem., 285, 16195, 10.1074/jbc.M110.107987 · DOI
  117. Shlyakhtenko, 2013, Atomic force microscopy studies of APOBEC3G oligomerization and dynamics, J. Struct. Biol., 184, 217, 10.1016/j.jsb.2013.09.008 · DOI
  118. Chelico, 2009, Stochastic properties of processive cytidine DNA deaminases AID and APOBEC3G, Philos. Trans. R. Soc. Lond. B Biol. Sci., 364, 583, 10.1098/rstb.2008.0195 · DOI
  119. Salter, 2014, Structural insights for HIV-1 therapeutic strategies targeting Vif, Trends Biochem. Sci., 39, 373, 10.1016/j.tibs.2014.07.001 · DOI
  120. Richards, 2015, The binding interface between human APOBEC3F and HIV-1 Vif elucidated by genetic and computational approaches, Cell Rep., 13, 1781, 10.1016/j.celrep.2015.10.067 · DOI
  121. Greeve, 1993, Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins, J. Lipid Res., 34, 1367, 10.1016/S0022-2275(20)36966-2 · DOI
  122. Smith, 2005, Mammalian C to U editing, Top. Curr. Biol., 12, 365
  123. Davidson, 1995, Proposed nomenclature for the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme: APOBEC-1, RNA, 1, 3
  124. Fossat, 2014, C to U RNA editing mediated by APOBEC1 requires RNA-binding protein RBM47, EMBO Rep., 15, 903, 10.15252/embr.201438450 · DOI · Paper page
  125. Blanc, 2005, Targeted deletion of the murine apobec-1 complementation factor (acf) gene results in embryonic lethality, Mol. Cell. Biol., 25, 7260, 10.1128/MCB.25.16.7260-7269.2005 · DOI
  126. Hirano, 1996, Targeted disruption of the mouse apobec-1 gene abolishes apolipoprotein B mRNA editing and eliminates apolipoprotein B48, J. Biol. Chem., 271, 9887, 10.1074/jbc.271.17.9887 · DOI
  127. Skuse, 1996, The neurofibromatosis type I messenger RNA undergoes base-modification RNA editing, Nuc. Acids Res., 24, 478, 10.1093/nar/24.3.478 · DOI
  128. Rosenberg, 2011, Transcriptome-wide sequencing reveals numerous APOBEC1 mRNA-editing targets in transcript 3′ UTRs, Nat. Struct. Mol. Biol., 18, 230, 10.1038/nsmb.1975 · DOI · Paper page
  129. Anant, 2000, An AU-rich sequence element (UUUN[A/U]U) downstream of the edited C in apolipoprotein B mRNA is a high-affinity binding site for Apobec-1: binding of Apobec-1 to this motif in the 3′ untranslated region of c-myc increases mRNA stability, Mol. Cell. Biol., 20, 1982, 10.1128/MCB.20.6.1982-1992.2000 · DOI
  130. Cappione, 1997, A potential role for NF1 mRNA editing in the pathogenesis of NF1 tumors, Am. J. Hum. Genet., 60, 305
  131. Mukhopadhyay, 2002, C–U editing of neurofibromatosis 1 mRNA occurs in tumors that express both the type II transcript and apobec-1, the catalytic subunit of the apolipoprotein B mRNA-editing enzyme, Am. J. Hum. Genet., 70, 38, 10.1086/337952 · DOI
  132. Pery, 2009, Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif, J. Virol., 83, 2374, 10.1128/JVI.01898-08 · DOI
  133. Anwar, 2013, Footprint of APOBEC3 on the genome of human retroelements, J. Virol., 87, 8195, 10.1128/JVI.00298-13 · DOI
  134. Kinomoto, 2007, All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition, Nuc. Acids Res., 35, 2955, 10.1093/nar/gkm181 · DOI
  135. Bogerd, 2006, APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells, Nuc. Acids Res., 34, 89, 10.1093/nar/gkj416 · DOI
  136. Chen, 2006, APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons, Curr. Biol., 16, 480, 10.1016/j.cub.2006.01.031 · DOI
  137. Muckenfuss, 2006, APOBEC3 proteins inhibit human LINE-1 retrotransposition, J. Biol. Chem., 281, 22161, 10.1074/jbc.M601716200 · DOI
  138. Stenglein, 2006, APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism, J. Biol. Chem., 281, 16837, 10.1074/jbc.M602367200 · DOI
  139. Chiu, 2006, High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition, Proc. Natl. Acad. Sci. U. S. A., 103, 15588, 10.1073/pnas.0604524103 · DOI
  140. Hulme, 2007, Selective inhibition of Alu retrotransposition by APOBEC3G, Gene, 390, 199, 10.1016/j.gene.2006.08.032 · DOI
  141. Esnault, 2005, APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses, Nature, 433, 430, 10.1038/nature03238 · DOI
  142. Letko, 2013, Vif proteins from diverse primate lentiviral lineages use the same binding site in APOBEC3G J, Virol., 87, 11861, 10.1128/JVI.01944-13 · DOI

Cited by

Sorted by citations

Metadata

Authors
Salter, J. D., Bennett, R. P., & Smith, H. C.
Venue
Trends in Biochemical Sciences
Publisher
Elsevier BV
Published
2016-07
Volume
41
Issue
7
Pages
578-594
ISSN
0968-0004
DOI
10.1016/j.tibs.2016.05.001
PMC
PMC4930407
Cited by
408
References
1
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review